

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
 Giorgio CALDERARI et al.) Group Art Unit: 1628
)
 Application No.: 13/902,132)
) Examiner: Shirley V. GEMBEH
 Filed: May 24, 2013)
)
 For: LIQUID PHARMACEUTICAL) Confirmation No.: 2532
 FORMULATIONS OF)
 PALONOSETRON)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

AMENDMENT AND RESPONSE TO OFFICE ACTION

In reply to the Office Action mailed August 8, 2013, please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims in this paper and begin on page 2.

Remarks/Arguments follow the amendment sections of this paper and begin on page 8.

Dr. Reddy's Laboratories, Ltd., et al.
v.
Helsinn Healthcare S.A., et al.
U.S. Patent No. 8,729,094

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-11. (Canceled)

12. (Currently Amended) A method for reducing the likelihood of cancer chemotherapy-induced nausea and vomiting, comprising intravenously administering to a human in need thereof the a pharmaceutical single-use, unit-dose formulation comprising a 5 mL sterile aqueous isotonic solution buffered at a pH of about 5.0 ± 0.5, said solution of claim 10, comprising:

about 0.05 mg/mL palonosetron hydrochloride based on the weight of its free base;

about 41.5 mg/mL mannitol;

about 0.5 mg/mL EDTA; and

a citrate buffer,

wherein said formulation is stable at 24 months when stored at room temperature, and

wherein said intravenous administration to said human occurs before the start of the cancer chemotherapy.

13. (Previously Presented) The method of claim 12, wherein said intravenous administration to said human occurs over a period of time of 10 to 60 seconds.

14. (Previously Presented) The method of claim 12, wherein said intravenous administration reduces the likelihood of acute nausea and vomiting in said human.

15. (Previously Presented) The method of claim 12, wherein said intravenous administration reduces the likelihood of delayed nausea and vomiting in said human.

16. (New) A method for reducing the likelihood of cancer chemotherapy-induced nausea and vomiting, comprising intravenously administering to a human in need thereof a pharmaceutical single-use, unit-dose formulation comprising a 5 mL sterile aqueous isotonic solution buffered at a pH of about 5.0 ± 0.5 , said solution comprising:

about 0.05 mg/mL palonosetron hydrochloride based on the weight of its free base;

from about 10 mg/mL to about 80 mg/mL mannitol; and

from about 0.3 mg/mL to about 0.7 mg/mL EDTA;

wherein said solution optionally comprises a citrate buffer,

wherein said formulation is stable at 24 months when stored at room temperature, and

wherein said intravenous administration to said human occurs before the start of the cancer chemotherapy.

17. (New) The method of claim 16, wherein said intravenous administration to said human occurs over a period of time of 10 to 60 seconds.

18. (New) The method of claim 16, wherein said intravenous administration reduces the likelihood of acute nausea and vomiting in said human.

19. (New) The method of claim 16, wherein said intravenous administration reduces the likelihood of delayed nausea and vomiting in said human.

20. (New) The method of claim 16, wherein said solution comprises from about 20 mg/mL to about 60 mg/mL mannitol.

21. (New) The method of claim 20, wherein said solution comprises from about 40 mg/mL to about 45 mg/mL mannitol.

22. (New) The method of claim 21, wherein said solution comprises about 41.5 mg/mL mannitol and about 0.5 mg/mL EDTA.

23. (New) The method of claim 16, wherein said solution comprises a citrate buffer.

24. (New) A method for reducing the likelihood of cancer chemotherapy-induced nausea and vomiting, comprising intravenously administering to a human in need thereof a pharmaceutical single-use, unit-dose formulation comprising a 5 mL sterile aqueous isotonic solution, said solution comprising:

about 0.05 mg/mL palonosetron hydrochloride based on the weight of its free base;

a tonicifying effective amount of mannitol; and

from about 0.3 mg/mL to about 0.7 mg/mL EDTA;

wherein said solution optionally comprises a citrate buffer and optionally has a pH of from about 5.0 ± 0.5 ,

wherein said formulation is stable at 24 months when stored at room temperature, and

wherein said intravenous administration to said human occurs before the start of the cancer chemotherapy.

25. (New) The method of claim 24, wherein said intravenous administration to said human occurs over a period of time of 10 to 60 seconds.

26. (New) The method of claim 24, wherein said intravenous administration reduces the likelihood of acute nausea and vomiting in said human.

27. (New) The method of claim 24, wherein said intravenous administration reduces the likelihood of delayed nausea and vomiting in said human.

28. (New) The method of claim 24, wherein said solution comprises a citrate buffer.

29. (New) The method of claim 24, wherein said solution is buffered at a pH of about 5.0 ± 0.5 .

30. (New) The method of claim 24, wherein said solution comprises from about 10 mg/mL to about 80 mg/mL mannitol.

31. (New) The method of claim 30, wherein said solution comprises from about 20 mg/mL to about 60 mg/mL mannitol.

32. (New) The method of claim 32, wherein said solution comprises about 41.5 mg/mL mannitol and about 0.5 mg/mL EDTA.

33. (New) A method for reducing the likelihood of cancer chemotherapy-induced nausea and vomiting, comprising intravenously administering to a human in need thereof a pharmaceutical single-use, unit-dose formulation comprising a 5 mL sterile aqueous isotonic solution buffered at a pH of about 5.0 ± 0.5 , said solution comprising:

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.